SOURCE: StockCall

StockCall

October 01, 2010 09:53 ET

Analyst Research on Savient Pharmaceuticals and Seattle Genetics -- The Dynamics at Work in Biotech Space

JOHANNESBURG, SOUTH AFRICA--(Marketwire - October 1, 2010) - www.stockcall.com/ offers investors comprehensive research on the biotechnology industry and has completed analytical research on Savient Pharmaceuticals Inc. (NASDAQ: SVNT) and Seattle Genetics Inc. (NASDAQ: SGEN). Register with us today at www.stockcall.com/ to have free access to these researches. 

In the biotechnologies industry companies must have large amounts of startup capital and live and die through their innovations. Millions of dollars are sunk into research and development (R&D) with the possibility of a return on the investment being slim. Even if biotech companies are successful in their inventions, it takes another mountain of cash to move the drug through the FDA approval process. Because of this many companies post losses for years before they can hopefully strike it rich. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the biotechnology industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on Savient Pharmaceuticals Inc. and Seattle Genetics Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html

A few companies in the industry are doing just that and have seen share prices jump drastically as some products test positively in clinical trials while others finally get FDA approval. Early this week Seattle Genetics Inc. saw its share prices soar as the biotech company announced that its cancer drug candidate showed encouraging results in a late-stage clinical trial. The company saw its rating upgraded to buy following the optimistic data. Investors looking for complimentary research on Seattle Genetics Inc. are welcome to sign up at www.stockcall.com/SGEN011010.pdf for our new report. 

Some biotech companies that are able to successfully bring a new drug onto the market are prime acquisition targets for larger industry players who want to capitalize on the innovation and increase their market share. Savient Pharmaceuticals Inc., which has recently received the blessing of the FDA for its gout treatment Krystexxa, looks like a prime takeover contender. Investors looking for free research on Savient Pharmaceuticals Inc. are welcome to sign up at www.stockcall.com/SVNT011010.pdf for our new report. 

The ability to produce successful products before funding runs out remains key to success in the industry. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information